Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Type:
Grant
Filed:
April 28, 2021
Date of Patent:
August 29, 2023
Assignee:
FORMA Therapeuetics, Inc.
Inventors:
Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu